311 studies found for:    HIV [CONDITION] AND ((anti-hiv OR antiretroviral) AND medicines) [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study
Condition: HIV Infections
Interventions: Drug: lopinavir;   Drug: atazanavir;   Drug: efavirenz;   Drug: fosamprenavir;   Drug: darunavir;   Drug: tipranavir;   Drug: ritonavir;   Drug: nevirapine;   Drug: zidovudine;   Drug: lamivudine;   Drug: tenofovir;   Drug: emtricitabine;   Drug: abacavir
22 Recruiting Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Conditions: HIV-1;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: E/C/F/TAF;   Drug: DRV;   Drug: Pre-existing ARV regimen
23 Recruiting Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
24 Recruiting A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK744;   Drug: GSK744 LA;   Drug: TMC278 LA;   Drug: ABC/3TC;   Drug: RPV
25 Unknown  Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
Conditions: HIV;   AIDS;   Tuberculosis
Interventions: Drug: Simultaneous ARV and antiMTB;   Drug: Deferred RV and antiMTB treatment
26 Recruiting Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition: HIV Infections
Interventions: Drug: Current ARV medications;   Drug: Current TB medications;   Drug: Current hormonal contraceptive medications
27 Recruiting Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
Conditions: HIV-1 Infection;   Kaposi's Sarcoma
Interventions: Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate;   Drug: etoposide
28 Recruiting Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression
Condition: Human Immunodeficiency Virus
Interventions: Drug: Atazanavir, ritonavir, lamivudine;   Drug: Atazanavir, Ritonavir, 2 NRTIs
29 Not yet recruiting Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
Conditions: HIV;   Pregnancy
Interventions: Drug: Raltegravir;   Drug: Lopinavir/Ritonavir
30 Unknown  Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: LPV/r;   Drug: PEG-IFNa 2a;   Drug: Ribavirin;   Drug: NUCS
31 Recruiting Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV
Conditions: HIV Infection;   Tuberculosis
Interventions: Drug: Lopinavir/Ritonavir;   Drug: Raltegravir;   Drug: Isoniazid;   Drug: Pyridoxine;   Drug: Pyrazinamide;   Drug: Ethambutol;   Drug: Rifabutin;   Drug: Rifampin
32 Not yet recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
33 Not yet recruiting DRV/r + RPV QD: Efficacy and Toxicity Reduction
Condition: HIV-positive Subjects With HIV-RNA <50 Copies/mL
Interventions: Drug: RPV + DRV/r;   Drug: subjects will continue the PI/r-containing regimen that is on-going at the time of enrollment.
34 Recruiting Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
Conditions: HIV-1 Infection;   Immunosuppression-related Infectious Disease
Interventions: Drug: DARUNAVIR;   Drug: ATAZANAVIR
35 Recruiting Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
Condition: HIV Infection
Interventions: Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
36 Not yet recruiting Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Conditions: Hepatitis C, Chronic;   HIV Infection
Interventions: Drug: Raltegravir;   Drug: Efavirenz
37 Recruiting Tissue Drug Levels of HIV Medications
Condition: Human Immunodeficiency Virus
Intervention: Drug: Initiation of anti-retroviral therapy
38 Recruiting On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men
Condition: HIV Infection
Interventions: Drug: Truvada;   Drug: Placebo
39 Recruiting Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
Conditions: HIV-1 Infection;   Pf Subclinical Parasitemia
Interventions: Drug: Lopinavir/ritonavir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz;   Drug: Nevirapine;   Drug: emtricitabine/tenofovir disoproxil fumarate;   Drug: trimethoprim/sulfamethoxazole
40 Recruiting A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: ABC/DTG/3TC FDC;   Drug: Ongoing cART regimen

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years